GMAB News and Press, Genmab A/S From 02/23/21

Image source: The Motley Fool. Genmab A/S (NASDAQ: GMAB) Q4 2020 Earnings Call Feb 23, 2021 , 12:00 p.m. ET Operator Continue reading For further details see: Genmab A/S (GMAB) Q4 2020 Earnings Call Transcript

Genmab A/S (GMAB) Q4 2020 Earnings Conference Call February 23, 2021, 12:00 ET Company Participants Jan van de Winkel - Co-Founder, President & CEO Anthony Pagano - EVP & CFO Anthony Mancini - EVP & COO Judith Klimovsky - EVP & Chief Development Officer Tahamtan Ahmadi - SVP C...

Genmab A/S (GMAB) today announced it would initiate a share repurchase program of up to 200,000 shares.The buyback will start on Feb. 24 and end no later than June 30 of this year.Genmab says it is conducting the repurchase to mitigate dilution caused by warrant exercises and honor commitment...

Genmab A/S (GMAB): FY GAAP EPS of DKK72.21.Revenue of DKK10.11B (+88.3% Y/Y) beats by DKK230M.Press Release For further details see: Genmab A/S beats on revenue

Genmab ([[GMAB]] -4.8%) announces repurchase of up to 200,000 shares.The purpose of the program is mitigating dilution from warrant exercises and honoring commitments under our restricted stock unit program.Completion expected no later than June 30, 2021.The company is entitled to suspend or ...

Genmab (GMAB) and Seagen (SGEN) announce the submission of a Biologics License Application ((BLA)) to the U.S. FDA seeking accelerated approval for tisotumab vedotin for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or a...

- Submission Based on Positive Pivotal innovaTV 204 Trial Results Presented at the European Society of Medical Oncology Virtual Congress 2020 - Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) today announced the submission of a Biologics License Application ...

Biotech stocks attracted maximum attention in 2020 due to the COVID-19 pandemic and a worldwide scramble to develop vaccines. Favorable news surrounding vaccines has boosted confidence generally that biotech companies will be successful in developing treatments for other critical diseases soo...

BMEZ delivered solid results throughout 2020, helped by the healthcare sector overall. This fund doesn't just invest in your typical healthcare companies though and tilts towards smaller and private investments. These companies are ripe for significant growth, at the same time, BM...

Genmab A/S ([[GMAB]] -1.5%) gets positive recommendation for marketing approval for its subcutaneous ofatumumab for the treatment of relapsing forms of multiple sclerosis in certain adults from the Committee for Medicinal Products for Human Use ((CHMP)).Ofatumumab is being developed and ...